Pasi Janne, M.D., Ph.D., Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Pasi Janne, M.D., Ph.D., Dana-Farber Cancer Institute

Caption

Pasi Janne, M.D., Ph.D., and colleagues are reporting in the New England Journal of Medicine that non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy.

Credit

Sam Ogden

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.